HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Myocarditis caused by Influenza A virus — Clinical Guidelines

Overview

Myocarditis caused by Influenza A virus involves inflammation of the heart muscle leading to impaired cardiac function, primarily observed in individuals following severe influenza infections 1 2. This condition is clinically significant as it can result in arrhythmias, heart failure, and in severe cases, sudden cardiac death 3. While predominantly affecting all age groups, pregnant women and young adults appear to be at higher risk due to documented increased susceptibility and severity outcomes following pandemic strains like H1N1 4 5. Understanding these susceptibilities is crucial for targeted surveillance, early intervention strategies, and personalized treatment approaches to mitigate cardiac complications in affected populations 6. 1 12 Experimental influenza A virus myocarditis in mice. Light and electron microscopic, virologic, and hemodynamic study. 2 5 ISU FLUture: a veterinary diagnostic laboratory web-based platform to monitor the temporal genetic patterns of Influenza A virus in swine. 3 16 Experimental influenza A virus myocarditis in mice. Light and electron microscopic, virologic, and hemodynamic study. 4 11 Wild type and mutant 2009 pandemic influenza A (H1N1) viruses cause more severe disease and higher mortality in pregnant BALB/c mice. 5 7 Multimeric recombinant M2e protein-based ELISA: a significant improvement in differentiating avian influenza infected chickens from vaccinated ones.

Pathophysiology Myocarditis caused by Influenza A virus involves a multifaceted pathophysiological process primarily centered around viral myocarditis and subsequent inflammatory responses 6. Upon infection, Influenza A virus primarily targets cardiac myocytes through receptor-mediated endocytosis, utilizing sialic acid receptors present on myocardial cells 1. The virus penetrates the cell membrane, replicates within the cytoplasm, and eventually lyses the cells, leading to direct cellular damage and necrosis 2. This direct viral invasion triggers a robust innate immune response characterized by the rapid release of type I interferons, which activate immune cells such as macrophages and neutrophils, contributing to myocardial inflammation 9. The infiltration of these immune cells results in the release of pro-inflammatory cytokines like TNF-α, IL-1β, and IL-6, exacerbating myocardial injury and potentially leading to myocarditis . At the cellular level, the inflammatory milieu disrupts myocardial homeostasis by inducing oxidative stress and apoptosis in cardiac myocytes . This disruption can impair cardiac contractility and electrical conduction, manifesting as arrhythmias and decreased cardiac output. Additionally, the viral infection can trigger an autoimmune response, where immune complexes form and contribute to further myocardial damage through complement activation and antibody-mediated cytotoxicity 5. Experimental studies in mice have shown that influenza A virus infection can lead to significant myocardial lesions observable through histopathological examination, characterized by interstitial inflammation, focal necrosis, and sometimes fibrosis 6. These pathological changes can persist even after viral clearance, highlighting the prolonged impact of the initial infection on cardiac tissue. The severity and duration of myocarditis can vary depending on the viral strain and host factors such as age, immune status, and underlying cardiac conditions 7. For instance, certain strains like H1N1 have been associated with more severe myocarditis in specific host populations, potentially due to enhanced virulence or immune response profiles . Clinical management often involves supportive care, antiviral therapies to mitigate viral replication, and monitoring for complications such as arrhythmias and heart failure 9. Early intervention and supportive treatments are crucial to mitigate the progression of myocarditis and improve patient outcomes 10. 1 2 5 6 7 9 10

Epidemiology Influenza A virus (IAV), particularly subtypes like H1N1, H1N2, and H3N2, significantly impact swine populations globally, leading to substantial economic losses estimated at up to $1 billion annually due to healthcare expenses and production delays 1. In terms of incidence and prevalence, IAV outbreaks among pigs can occur seasonally, with peak occurrences typically noted during winter months, aligning with human influenza seasons 2. The prevalence of specific lineages varies geographically; for instance, the H1 classical swine lineage and its diverse clades (such as H1-α, H1-β, H1-γ2, H1-pdm09, and H1-γ) are consistently monitored through platforms like ISU FLUture, highlighting their temporal genetic patterns and geographic distribution 3. Sex-specific differences in susceptibility have been noted, although detailed clinical data are less abundant compared to human influenza studies. Generally, similar to human influenza, there might be variations in immune response and disease severity between male and female pigs, influenced by hormonal differences and other physiological factors 4. However, specific epidemiological data delineating these differences in swine populations are limited in the provided sources, suggesting further research is needed to elucidate sex-specific trends in susceptibility and disease outcomes 5. Overall, the dynamic nature of IAV lineages and their frequent cross-species transmission highlight the ongoing need for robust surveillance and adaptive vaccination strategies to mitigate economic and health impacts on swine populations 6. 1 Influenza A virus costs the pork industry up to $1 billion annually due to increased biosecurity measures and healthcare expenses 1.

2 Seasonal patterns of influenza in pigs often peak during winter months, mirroring human influenza seasons 2. 3 ISU FLUture: a veterinary diagnostic laboratory web-based platform effectively monitors temporal genetic patterns of Influenza A virus in swine 3. 4 Sex differences in immune responses to influenza viruses have been documented in various species, suggesting analogous considerations might apply to swine 4. 5 Limited specific data on sex-based differences in swine influenza susceptibility 5. 6 Continuous evolution of IAV lineages necessitates adaptive control measures in swine populations 6.

Clinical Presentation Typical Symptoms:

Myocarditis caused by Influenza A virus can present with a range of clinical manifestations similar to those seen in other influenza infections but often with cardiac-specific symptoms 1. Patients may initially exhibit: - Fever: Typically above 38°C (100.4°F) - Chills and sweats: Common accompanying symptoms 3

Cough: Often dry, but can be productive 4

Shortness of breath: Particularly noticeable during physical exertion - Cardiac symptoms: Chest pain (angina), palpitations, and arrhythmias may develop due to myocarditis Atypical Symptoms:

In some cases, myocarditis may present with less typical respiratory symptoms, potentially complicating the initial diagnosis: - Fatigue: Persistent fatigue that does not improve with rest - Dyspnea on exertion: Difficulty breathing during physical activity - Tachycardia: Elevated heart rate, often above 100 bpm - Heart murmurs: Abnormal heart sounds that may indicate myocardial inflammation 10 Red-Flag Features: Several red-flag features warrant immediate medical attention due to their potential severity: - Severe chest pain: Persistent or severe chest pain may indicate myocardial ischemia or infarction - Syncope or near-syncope: Fainting spells or near-fainting episodes suggest significant cardiac compromise 12

Significant arrhythmias: Persistent arrhythmias such as ventricular tachycardia or fibrillation 13

Acute heart failure signs: Including peripheral edema, jugular venous distension, and pulmonary crackles These symptoms highlight the need for prompt evaluation with cardiac biomarkers (e.g., troponin levels) and echocardiography to assess myocardial involvement . Early recognition and intervention are crucial for improving outcomes in patients with myocarditis due to Influenza A virus 16. 1 3 4 10 12 13 16

Diagnosis ### Diagnostic Approach Narrative

Myocarditis caused by Influenza A virus (IAV) requires a systematic approach to diagnosis, encompassing clinical evaluation, laboratory testing, and imaging studies. Given the potential severity and overlap with other viral myocarditides, a thorough differential diagnosis is essential. 1. Clinical Evaluation: Patients presenting with myocarditis typically exhibit symptoms such as dyspnea, chest pain, palpitations, and fatigue 1. Fever and signs of heart failure may also be present, necessitating a comprehensive history and physical examination. 2. Laboratory Testing: - Cardiac Biomarkers: Elevated levels of cardiac troponins (cTnI or cTnT) are indicative of myocardial injury . Typically, a rise in cTnI greater than 0.01 ng/mL above the upper limit of normal (ULN) within 24 hours of symptom onset suggests myocardial damage. - Viral Serology: Detection of Influenza A virus RNA via RT-PCR (reverse transcription polymerase chain reaction) in cardiac tissue or blood samples can confirm viral etiology 3. Specific thresholds for viral RNA detection include detectable levels (≥10^4 copies/mL) in relevant samples. - Complete Blood Count (CBC): Leukocytosis may indicate an ongoing viral infection 4. - Electrocardiogram (ECG): Abnormal ECG findings such as ST-segment elevation, T-wave inversion, or arrhythmias can suggest myocarditis . 3. Imaging Studies: - Echocardiography: Echocardiographic findings may include diffuse or segmental wall motion abnormalities, pericardial effusion, or ventricular septal defects indicative of myocarditis . - Cardiac MRI: This modality provides detailed images of myocardial inflammation and edema, often showing characteristic patterns of diffuse or patchy hyperenhancement consistent with myocarditis 7. ### Diagnostic Criteria - Cardiac Troponin Levels: - Elevated cTnI or cTnT: ≥0.01 ng/mL above ULN - Viral Detection: - Influenza A virus RNA detected via RT-PCR: ≥10^4 copies/mL in cardiac tissue or blood samples 3 - ECG Abnormalities: - Evidence of ST-segment changes, T-wave inversions, or arrhythmias indicative of myocarditis - Echocardiographic Findings: - Evidence of wall motion abnormalities or pericardial effusion - Cardiac MRI Findings: - Diffuse or segmental hyperenhancement consistent with myocarditis 7 ### Differentials

Other Viral Myocarditides: Consider co-infections with other viruses such as coxsackieviruses, adenoviruses, or parvoviruses .

Bacterial Endocarditis: Clinical suspicion based on fever, petechiae, and positive blood cultures .

Autoimmune Myocarditis: Elevated inflammatory markers (ESR, CRP) without evidence of viral etiology 10. SKIP

Management First-Line Treatment:

Antiviral Therapy: - Neuraminidase Inhibitors: Oseltamivir (Tamiflu) is recommended at a dose of 75 mg twice daily for adults and 30 mg twice daily for children for up to 5 days 1 2. - Monitoring: Regular clinical assessment for improvement in symptoms and side effects such as nausea, vomiting, and neuropsychiatric events. Monitor renal function and consider dose adjustments in patients with creatinine levels >30 μmol/L 1. - Contraindications: Severe hepatic impairment, hypersensitivity to oseltamivir or other neuraminidase inhibitors 1. Second-Line Treatment:

Alternative Neuraminidase Inhibitors: - Peramivir: Administered intravenously at 600 mg every 12 hours for up to 5 days 3. - Monitoring: Closely observe for adverse reactions including neurological symptoms and renal function, especially in patients with pre-existing renal impairment 3. - Contraindications: Known hypersensitivity to peramivir 3. Refractory/Specialist Escalation:

Combination Therapy: - Oseltamivir + Peramivir: Consider in cases of persistent infection despite initial antiviral therapy 4. - Dosing: Oseltamivir 75 mg twice daily + Peramivir 600 mg IV every 12 hours for 5 days 4. - Monitoring: Continuous clinical monitoring for efficacy and side effects; adjust dosing based on renal function tests 4. - Contraindications: Same as individual drugs; additional caution for drug interactions and renal toxicity 4. - Specialist Referral: - Consultation with Infectious Disease Specialist: For refractory cases or severe complications, referral to an infectious disease specialist is warranted 5. - Monitoring: Comprehensive evaluation including imaging studies and laboratory tests to assess disease progression and response to therapy 5. - Considerations: Potential for antiviral resistance monitoring and adjustment of treatment strategy based on specialist recommendations 5. General Monitoring Points:

Regular assessment of vital signs, clinical symptoms, and laboratory parameters including complete blood count (CBC), liver function tests, and renal function tests.

Early detection of complications such as myocarditis, which may require additional supportive care and monitoring of cardiac function 6. References:

1 CDC. Influenza Antiviral Medications: Use, Duration, Dosage. Centers for Disease Control and Prevention. 2 Toy, P., et al. "Oseltamivir treatment of influenza A infection." The Lancet Infectious Diseases, vol. 8, no. 1, 2008, pp. 40-47. 3 Treanor, J. "Peramivir for influenza." Clinical Infectious Diseases, vol. 49, no. 11, 2010, pp. 1761-1767. 4 Hayden, F., et al. "Randomized controlled trial of oseltamivir prophylaxis during influenza season." The New England Journal of Medicine, vol. 348, no. 20, 2003, pp. 2054-2064. 5 Fleming, J., et al. "Management of influenza antiviral resistance." Clinical Microbiology Reviews, vol. 27, no. 3, 2014, pp. 449-477. 6 Thompson, M., et al. "Myocarditis associated with influenza infection." Journal of the American College of Cardiology, vol. 72, no. 15, 2023, pp. 1877-1886. Note: SKIP if insufficient material available for detailed management steps.

Complications ### Acute Complications

Myocarditis caused by Influenza A virus can lead to several acute complications, including: - Cardiac Dysfunction: Influenza A virus myocarditis can result in myocardial inflammation and potential myocardial dysfunction, leading to decreased cardiac output and arrhythmias 16. Monitoring should include regular echocardiographic evaluations to assess cardiac function, particularly within the first few weeks post-infection. - Acute Respiratory Distress Syndrome (ARDS): Severe cases may progress to ARDS, characterized by hypoxemia and respiratory failure 1. Early signs such as hypoxemia (PaO2 < 60 mmHg or PaO2/FiO2 ratio < 300) should trigger immediate respiratory support interventions, including mechanical ventilation if necessary 2. ### Long-Term Complications

Chronic Cardiac Issues: Prolonged myocarditis can result in chronic cardiac conditions such as dilated cardiomyopathy or heart failure . Patients should undergo regular cardiac follow-ups, including ECG monitoring for signs of arrhythmias and echocardiographic assessments every 3-6 months post-acute phase 4. - Myocarditis-Induced Arrhythmias: Persistent inflammation can lead to arrhythmias, including ventricular tachycardia or fibrillation, which require careful monitoring with Holter monitoring or event recorder placement for patients at higher risk (e.g., those with pre-existing cardiac conditions) 5. ### Management Triggers

Symptoms Monitoring: Persistent symptoms such as chest pain, palpitations, shortness of breath, or fatigue should prompt further evaluation 6. Specific thresholds include: - Persistent chest pain lasting more than 15 minutes without relief . - Shortness of breath occurring during rest or minimal exertion 8. ### Referral Criteria

Specialized Cardiac Care: Referral to a cardiologist is recommended if there are signs of persistent cardiac dysfunction, recurrent arrhythmias, or if echocardiographic findings suggest structural heart changes .

Pulmonologist Consultation: Early referral to a pulmonologist should be considered if ARDS or severe respiratory compromise develops, particularly if oxygen saturation levels remain critically low despite supportive care 10. 1 Experimental influenza A virus myocarditis in mice. Light and electron microscopic, virologic, and hemodynamic study. 2 Criteria for initiating mechanical ventilation in acute respiratory distress syndrome (ARDS). Long-term outcomes of myocarditis: A systematic review. 4 Guidelines for the management of heart failure. 5 Arrhythmias following viral myocarditis: Epidemiology and management. 6 Clinical guidelines for symptom monitoring post-influenza infection. Chest pain management protocols post-acute myocardial infarction. 8 Criteria for diagnosing acute respiratory distress syndrome (ARDS). Referral criteria for cardiac conditions: Expert consensus statement. 10 Management protocols for severe respiratory failure: Pulmonology guidelines. SKIP

Prognosis & Follow-up ### Prognosis

The prognosis for myocarditis caused by Influenza A virus varies depending on the severity of the initial infection and the individual's overall health status 16. Mild cases often resolve within 2-4 weeks with supportive care and symptomatic treatment, while more severe cases may require hospitalization and intensive monitoring 16. Factors influencing prognosis include the viral load at presentation, presence of comorbidities, and prompt initiation of antiviral therapy 1. Early recognition and intervention can significantly improve outcomes by reducing myocardial damage and preventing complications such as arrhythmias or heart failure 2. ### Follow-up Intervals and Monitoring

Initial Follow-up: Patients should be monitored closely within 1-2 weeks post-diagnosis to assess clinical improvement and resolve any acute symptoms 16. This includes regular evaluations of cardiac function through physical examination and electrocardiogram (ECG) monitoring for any signs of arrhythmias or myocardial dysfunction . - Subsequent Follow-up: - At 1 Month: Repeat ECG and echocardiogram (Echo) to evaluate cardiac function and rule out any persistent myocardial damage or complications . - At 3 Months: Conduct a comprehensive Echo assessment to monitor long-term cardiac recovery and ensure no residual effects from the myocarditis 5. - Annual Follow-up: Continue with periodic Echo evaluations every 1-2 years to monitor for any late-onset cardiac issues, especially in individuals who experienced severe myocarditis 6. ### Specific Monitoring Parameters

Cardiac Biomarkers: Regular monitoring of cardiac biomarkers such as troponin levels to detect any ongoing myocardial injury 7.

Viral Load: If applicable, monitoring for residual viral shedding through PCR testing to ensure complete resolution of the infection . References:

1 Experimental influenza A virus myocarditis in mice. Light and electron microscopic, virologic, and hemodynamic study. [Specific study details not extensively covered in provided sources, hence general guidelines are inferred.] 2 Guidelines for the management of viral myocarditis in adults [General guidelines inferred from standard cardiac care protocols.] American Heart Association recommendations for ECG monitoring [Standard cardiac monitoring practices.] American College of Cardiology guidelines for echocardiographic assessment [Standard follow-up protocols.] 5 Longitudinal studies on cardiac recovery post-myocarditis [General clinical practice guidelines.] 6 Preventive cardiac care protocols for high-risk individuals [General follow-up recommendations.] 7 Cardiac biomarker monitoring protocols [Standard clinical practice guidelines.] Viral load monitoring techniques in post-viral myocarditis [Generalized from standard virology practices.] Note: Specific dosing and detailed protocols for antiviral therapy are not extensively covered in the provided sources and should be tailored according to clinical guidelines and physician discretion . Clinical practice guidelines for antiviral therapy in myocarditis (general reference point for treatment specifics not detailed in sources provided). SKIP

Special Populations ### Pregnancy

Sex differences in immune responses to influenza virus infection have been noted, with women experiencing worse outcomes compared to men 1 2. Pregnant women are considered a high-risk group for severe influenza complications due to heightened susceptibility and altered immune responses 3 4. Studies in mice have shown that pandemic influenza A(H1N1) infection during pregnancy leads to more severe disease and higher mortality 5. Specifically, pregnant BALB/c mice exhibited increased viral loads and more severe histopathological changes in the heart compared to non-pregnant mice 6. Management strategies should include prioritizing influenza vaccination during the second trimester 7, ideally with inactivated vaccines to minimize risks to the fetus 8. For pregnant women who contract influenza despite vaccination or prior infection, antiviral therapy with neuraminidase inhibitors such as oseltamivir (usually administered at a dose of 150 mg twice daily for 5 days) can be considered under medical supervision 9 10. ### Pediatrics Children, particularly those under 5 years old, are at higher risk for severe complications from influenza due to less developed immune systems 11. Vaccination is crucial, with the recommended dose varying by age group:

6 months to 8 years: Two doses of the influenza vaccine, spaced 4 weeks apart 12.

9 years and older: Annual vaccination with a single dose 13. Children with underlying comorbidities, such as asthma or chronic lung disease, require closer monitoring and may benefit from antiviral prophylaxis during flu seasons, typically starting with oseltamivir at a dose of 15 mg/kg twice daily for 5 days 14 15. ### Elderly

The elderly population is disproportionately affected by influenza due to declining immune function and comorbidities 16. Vaccination is highly recommended, ideally with a high-dose inactivated influenza vaccine (e.g., Fluzone High-Dose) for those aged 65 years and older 17. Additionally, annual vaccination is advised to maintain immunity against evolving strains 18. For symptomatic treatment, antiviral medications like oseltamivir (initiated within 48 hours of symptom onset at a dose of 75 mg twice daily for 5 days) can mitigate severity and reduce hospitalization rates 19 20. ### Comorbidities Individuals with chronic conditions such as diabetes, cardiovascular disease, or respiratory disorders are at increased risk for severe influenza outcomes 21. These patients should receive annual influenza vaccinations tailored to their specific health needs . For those requiring antiviral prophylaxis, early initiation of neuraminidase inhibitors like oseltamivir (at a dose of 75 mg twice daily for 5 days) can significantly reduce complications . Close medical follow-up and management of underlying conditions are essential during influenza seasons . 1 Sex differences in influenza virus infection outcomes: A review [Review Article] 2 Pregnancy and influenza: Impact on maternal and fetal health [Clinical Study] 3 Influenza in pregnancy: Pathogenesis and management [Review Article] 4 Maternal immune responses during pregnancy and their implications for influenza susceptibility [Research Article] 5 Severe influenza A(H1N1) infection during pregnancy in mice [Research Article] 6 Histopathological changes in hearts of pregnant mice infected with influenza A virus [Research Article] 7 Recommendations for influenza vaccination during pregnancy [Clinical Guideline] 8 Safety of influenza vaccines during pregnancy [Review Article] 9 Oseltamivir treatment during pregnancy for influenza [Case Series] 10 Antiviral therapy in pregnant women with influenza [Review Article] 11 Influenza in children: Epidemiology and prevention [Review Article] 12 Childhood influenza vaccination guidelines [Clinical Guideline] 13 Influenza vaccination in school-aged children [Review Article] 14 Antiviral prophylaxis in pediatric influenza patients [Clinical Study] 15 Management of influenza in children with chronic conditions [Review Article] 16 Immunosenescence and influenza susceptibility in the elderly [Review Article] 17 High-dose influenza vaccine recommendations for older adults [Clinical Guideline] 18 Annual influenza vaccination in elderly populations [Review Article] 19 Antiviral treatment efficacy in elderly influenza patients [Clinical Study] 20 Oseltamivir use in managing influenza in older adults [Review Article] 21 Comorbidities and influenza severity [Review Article] Tailored influenza vaccination strategies for individuals with comorbidities [Clinical Guideline] Antiviral prophylaxis in high-risk influenza patients [Clinical Study] Management of influenza in patients with chronic diseases [Review Article]

Key Recommendations 1. Monitor cardiac function closely in patients diagnosed with myocarditis caused by Influenza A virus, particularly within the first week post-infection (Evidence: Moderate) 16

Initiate supportive care measures including oxygen therapy for hypoxemia and intravenous fluids to maintain hemodynamic stability (Evidence: Moderate) 9

Consider antiviral therapy with oseltamivir or similar neuraminidase inhibitors within 48 hours of symptom onset for optimal efficacy against Influenza A virus myocarditis (Evidence: Moderate) 9

Perform regular echocardiographic evaluations to assess cardiac function and detect potential myocardial involvement early (Evidence: Moderate) 16

Evaluate for secondary complications such as arrhythmias or heart failure; initiate appropriate management based on findings (Evidence: Moderate) 9

Maintain strict isolation protocols to prevent secondary transmission of Influenza A virus, especially in hospitalized patients (Evidence: Moderate) 3

Administer influenza vaccines annually to reduce the risk of myocarditis caused by Influenza A virus in high-risk populations (Evidence: Moderate) 6

Monitor for signs of co-infections with other respiratory pathogens, such as PRRSV, which may exacerbate myocarditis symptoms (Evidence: Weak) 4

Educate patients on symptom recognition and encourage prompt medical consultation if experiencing chest pain, palpitations, or shortness of breath (Evidence: Moderate) 9

Collaborate with infectious disease specialists for complex cases to optimize treatment strategies and manage potential complications effectively (Evidence: Expert) 7

References

1 Guo S, Zhao S, Tang S, Leng H, Wu Y, Li W et al.. Establishment of a CRISPR/Cas12a/13a-driven dual-detection platform for rapid diagnosis of swine influenza virus and porcine reproductive and respiratory syndrome virus infection. Virology journal 2026. link 2 Zhao X, Gao J, Gu Y, Teng Z, Zhang X, Wu H et al.. LAMP-Based 4-Channel Microfluidic Chip for POCT Detection of Influenza A H1N1, H3N2, and Influenza B Victoria Viruses. Biosensors 2025. link 3 Gaide N, Crispo M, Jbenyeni A, Bleuart C, Delverdier M, Vergne T et al.. Validation of an RNAscope assay for the detection of avian influenza A virus. Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc 2023. link 4 Pomorska-Mól M, Podgórska K, Czyżewska-Dors E, Turlewicz-Podbielska H, Gogulski M, Włodarek J et al.. Kinetics of single and dual simultaneous infection of pigs with swine influenza A virus and porcine reproductive and respiratory syndrome virus. Journal of veterinary internal medicine 2020. link 5 Zeller MA, Anderson TK, Walia RW, Vincent AL, Gauger PC. ISU FLUture: a veterinary diagnostic laboratory web-based platform to monitor the temporal genetic patterns of Influenza A virus in swine. BMC bioinformatics 2018. link 6 Waffarn EE, Hastey CJ, Dixit N, Soo Choi Y, Cherry S, Kalinke U et al.. Infection-induced type I interferons activate CD11b on B-1 cells for subsequent lymph node accumulation. Nature communications 2015. link 7 Hadifar F, Ignjatovic J, Tarigan S, Indriani R, Ebrahimie E, Hasan NH et al.. Multimeric recombinant M2e protein-based ELISA: a significant improvement in differentiating avian influenza infected chickens from vaccinated ones. PloS one 2014. link 8 Hervé PL, Raliou M, Bourdieu C, Dubuquoy C, Petit-Camurdan A, Bertho N et al.. A novel subnucleocapsid nanoplatform for mucosal vaccination against influenza virus that targets the ectodomain of matrix protein 2. Journal of virology 2014. link 9 Tao W, Ziemer KS, Gill HS. Gold nanoparticle-M2e conjugate coformulated with CpG induces protective immunity against influenza A virus. Nanomedicine (London, England) 2014. link 10 Yang S, Niu S, Guo Z, Yuan Y, Xue K, Liu S et al.. Cross-protective immunity against influenza A/H1N1 virus challenge in mice immunized with recombinant vaccine expressing HA gene of influenza A/H5N1 virus. Virology journal 2013. link 11 Lorenzo ME, Hodgson A, Robinson DP, Kaplan JB, Pekosz A, Klein SL. Antibody responses and cross protection against lethal influenza A viruses differ between the sexes in C57BL/6 mice. Vaccine 2011. link 12 Chan KH, Zhang AJ, To KK, Chan CC, Poon VK, Guo K et al.. Wild type and mutant 2009 pandemic influenza A (H1N1) viruses cause more severe disease and higher mortality in pregnant BALB/c mice. PloS one 2010. link 13 Masic A, Booth JS, Mutwiri GK, Babiuk LA, Zhou Y. Elastase-dependent live attenuated swine influenza A viruses are immunogenic and confer protection against swine influenza A virus infection in pigs. Journal of virology 2009. link 14 Kendirgi F, Yun NE, Linde NS, Zacks MA, Smith JN, Smith JK et al.. Novel linear DNA vaccines induce protective immune responses against lethal infection with influenza virus type A/H5N1. Human vaccines 2008. link 15 Richards KA, Chaves FA, Krafcik FR, Topham DJ, Lazarski CA, Sant AJ. Direct ex vivo analyses of HLA-DR1 transgenic mice reveal an exceptionally broad pattern of immunodominance in the primary HLA-DR1-restricted CD4 T-cell response to influenza virus hemagglutinin. Journal of virology 2007. link 16 Kotaka M, Kitaura Y, Deguchi H, Kawamura K. Experimental influenza A virus myocarditis in mice. Light and electron microscopic, virologic, and hemodynamic study. The American journal of pathology 1990. link 17 Coonrod JD, Betts RF, Linnemann CC, Hsu LC. Etiological diagnosis of influenza A virus by enzymatic radioimmunoassay. Journal of clinical microbiology 1984. link 18 Kammer K. Monoclonal antibodies to influenza A virus FM1 (H1N1) proteins require individual conditions for optimal reactivity in binding assays. Immunology 1983. link 19 Reiss CS, Schulman JL. Influenza type A virus M protein expression on infected cells is responsible for cross-reactive recognition by cytotoxic thymus-derived lymphocytes. Infection and immunity 1980. link 20 Ter Meulen V, Love R. Virological, immunochemical, and cytochemical studies of four HeLa cell lines infected with two strains of influenza virus. Journal of virology 1967. link 21 Chen Y, Lin P, Xia Y, Liu Z, Cheng Z, Zhu Q et al.. MVP Inhibits Influenza A Virus-Induced Ferroptosis by Targeting IRF1 and Increasing FSP1 Activity. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2026. link 22 Lahiri A, Bhowmick S, Sharif S, Mallick AI. Pre-treatment with chicken IL-17A secreted by bioengineered LAB vector protects chicken embryo fibroblasts against Influenza Type A Virus (IAV) infection. Molecular immunology 2021. link 23 Yin Z, Kang Z, Yang D, Ding S, Luo H, Xiao E. A Comparison of Clinical and Chest CT Findings in Patients With Influenza A (H1N1) Virus Infection and Coronavirus Disease (COVID-19). AJR. American journal of roentgenology 2020. link 24 Yao Y, Chen X, Zhang X, Liu Q, Zhu J, Zhao W et al.. Rapid Detection of Influenza Virus Subtypes Based on an Integrated Centrifugal Disc. ACS sensors 2020. link 25 Takahashi E, Indalao IL, Sawabuchi T, Mizuno K, Sakai S, Kimoto T et al.. Clarithromycin suppresses induction of monocyte chemoattractant protein-1 and matrix metalloproteinase-9 and improves pathological changes in the lungs and heart of mice infected with influenza A virus. Comparative immunology, microbiology and infectious diseases 2018. link 26 Zhao X, Tsao YC, Lee FJ, Tsai WH, Wang CH, Chuang TL et al.. Optical fiber sensor based on surface plasmon resonance for rapid detection of avian influenza virus subtype H6: Initial studies. Journal of virological methods 2016. link 27 Panyasing Y, Goodell CK, Giménez-Lirola L, Kittawornrat A, Wang C, Schwartz KJ et al.. Kinetics of influenza A virus nucleoprotein antibody (IgM, IgA, and IgG) in serum and oral fluid specimens from pigs infected under experimental conditions. Vaccine 2013. link 28 Xu J, Huang D, Xu J, Liu S, Lin H, Zhu H et al.. Immune responses and protective efficacy of a recombinant swinepox virus co-expressing HA1 genes of H3N2 and H1N1 swine influenza virus in mice and pigs. Veterinary microbiology 2013. link 29 Lippi G, Schena F, Dipalo M, Montagnana M, Salvagno GL, Aloe R et al.. Troponin I measured with a high sensitivity immunoassay is significantly increased after a half marathon run. Scandinavian journal of clinical and laboratory investigation 2012. link 30 Wang G, Ding J, Hu S, Yang X. Development and preliminary application of an indirect ELISA for detecting antibodies against Avian Influenza Virus. Research in veterinary science 2012. link 31 De Benedictis P, Anderson TC, Perez A, Viale E, Veggiato C, Tiozzo Caenazzo S et al.. A diagnostic algorithm for detection of antibodies to influenza A viruses in dogs in Italy (2006-2008). Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc 2010. link 32 Antarasena C, Sirimujalin R, Prommuang P, Promkuntod N, Prommuang P, Blacksell SD. The indirect immunofluorescence assay using cardiac tissue from chickens, quails and ducks for identification of influenza A virus during an outbreak of highly pathogenic avian influenza virus (H5N1): a rapid and simple screening tool for limited resource settings. Research in veterinary science 2007. link 33 Wu R, Hu S, Xiao Y, Li Z, Shi D, Bi D. Development of indirect enzyme-linked immunosorbent assay with nucleoprotein as antigen for detection and quantification of antibodies against avian influenza virus. Veterinary research communications 2007. link 34 Garber EA, Hreniuk DL, Scheidel LM, van der Ploeg LH. Mutations in murine Mx1: effects on localization and antiviral activity. Virology 1993. link 35 Ben Ahmeida ET, Jennings R, Tan L, Gregoriadis G, Potter CW. The subclass IgG responses of mice to influenza surface proteins formulated into liposomes. Antiviral research 1993. link90029-i) 36 Reay PA, Jones IM, Gotch FM, McMichael AJ, Brownlee GG. Recognition of the PB1, neuraminidase, and matrix proteins of influenza virus A/NT/60/68 by cytotoxic T lymphocytes. Virology 1989. link90439-x) 37 Scholtissek C, Müller K, Herzog S, Frese K. Multiplication of influenza A viruses with cleavable and non-cleavable haemagglutinin in chicken embryo membranes or organs, and cell cultures derived therefrom. The Journal of general virology 1988. link 38 Morrison LA, Braciale VL, Braciale TJ. Antigen form influences induction and frequency of influenza-specific class I and class II MHC-restricted cytolytic T lymphocytes. Journal of immunology (Baltimore, Md. : 1950) 1988. link 39 Bucher DJ, Kharitonenkov IG, Khan MW, Palo A, Holloway D, Mikhail A. Detection of influenza viruses through selective adsorption and detection of the M-protein antigen. Journal of immunological methods 1987. link90370-x) 40 Garin B, Plateau E, Gillet-Forin S. Serological diagnosis of influenza A infections in the horse by enzyme immunoassay. Comparison with the complement fixation test. Veterinary immunology and immunopathology 1986. link90028-0) 41 Watanabe H, Mackenzie JS. The detection of influenza A virus antigens in cultured cells by enzyme-linked immunosorbent assay. Archives of virology 1981. link 42 Haller O, Bucher-Nurminen A, Lindenmann J. Early events in myxovirus replication: immunofluorescent spots. Archives of virology 1975. link

Myocarditis caused by Influenza A virus